To view the PDF file, sign up for a MySharenet subscription.

Afrox Healthcare Limited - Offer by Bidco to acquire the entire share capital of

Release Date: 17/11/2003 09:00
Code(s): AHH BRN BRT MDC
Wrap Text

Afrox Healthcare Limited - Offer by Bidco to acquire the entire share capital of Afrox Healthcare Limited BUSINESS VENTURE INVESTMENTS NO. 790 AFROX HEALTHCARE LIMITED (PROPRIETARY) LIMITED (Incorporated in the Republic of (Incorporated in the Republic of South South Africa) Africa) (Registration number: 1985/001313/06) (Registration number: 2003/002733/07) Share code: AHH ("Bidco") ISIN: ZAE000022059 ("Ahealth") BRIMSTONE INVESTMENT CORPORATION LIMITED MVELAPHANDA STRATEGIC INVESTMENTS (Incorporated in the Republic of South (PROPRIETARY) LIMITED (Incorporated Africa) in the Republic of South Africa) (Registration number: 1995/010442/06) (Registration number: 1998/007485/07) Share code: BRT ("Mvelaphanda") ISIN: ZAE000015277 Share code: BRN ISIN: ZAE000015285 ("Brimstone") MEDI-CLINIC CORPORATION LIMITED (Incorporated in the Republic of South Africa) Registration number: 1983/010725/06 Share code: MDC ISIN: ZAE000004370 ("Medi-Clinic") JOINT ANNOUNCEMENT OF AN OFFER BY BIDCO TO ACQUIRE THE ENTIRE ISSUED SHARE CAPITAL OF AFROX HEALTHCARE ("THE OFFER") AND WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT 1. INTRODUCTION Pursuant to the further joint cautionary announcement published by African Oxygen Limited ("Afrox") and Ahealth on the Securities Exchange News Service ("SENS") on Monday, 6 October 2003, Rothschild and Deutsche Securities are authorised to announce that Bidco has submitted an offer to acquire the entire issued share capital of Ahealth for a cash consideration per share of R13.85. The cash consideration shall be escalated at an effective rate of 5.6% per annum from 1 October 2003, being the effective date, to the scheme operative date or the day on which the conditions of the alternative offer are fulfilled. For illustrative purposes, assuming the scheme operative date is 30 April 2004, the total consideration payable per Ahealth share ("Offer consideration") is as follows: R Cash consideration 13.85 Escalation at an effective rate of 5.6% per 0.45 annum Offer consideration 14.30 Final dividend declared for the year ended 30 0.40 September 2003* Composite amount 14.70 * Ahealth shareholders registered as such on 23 January 2004 will receive the final dividend of 40 cents per share declared by Ahealth on 29 October 2003 in respect of Ahealth"s financial year ended 30 September 2003. It is intended that the Offer will be effected by means of a scheme of arrangement in terms of section 311 of the Companies Act, (Act 61 of 1973) as amended (the "Act"), between Ahealth and its shareholders (the "Scheme"). If the Scheme fails to take effect and become operative on or before 31 May 2004, unless the only outstanding condition on that date is obtaining all of the approvals in terms of the Competition Act, in which event the date of 31 May 2004 shall be extended to 31 July 2004, an alternative sale will take effect whereby Bidco will purchase the Ahealth shares held by Afrox, followed by a mandatory offer to Ahealth minority shareholders ("the alternative offer") in terms of the Securities Regulation Code on Takeovers and Mergers and the Rules of the Securities Regulation Panel ("SRP"). Bidco has been incorporated solely for the purpose of acquiring the issued share capital of Ahealth. A consortium of Black Economic Empowerment investors ("the BEE Consortium"), led by Brimstone and Mvelaphanda will subscribe for approximately 75% of Bidco"s equity. The BEE Consortium includes nationally and regionally based doctor and empowerment groupings ensuring broad based empowerment. Medi-Clinic, a private hospital company listed on the JSE Securities Exchange South Africa ("JSE"), will subscribe for a minority non- controlling shareholding in Bidco of approximately 25%. Medi-Clinic and its holding company Remgro Limited ("Remgro") are facilitating the transaction funding provided by ABSA Bank Limited ("ABSA"), which has enabled Bidco to make the Offer. BOC Holdings, the controlling shareholder of Afrox, which holds 154,603,934 Ahealth shares being 69% of Ahealth"s issued share capital, has irrevocably undertaken to vote in favour of the shareholder resolutions necessary to approve the disposal by Afrox of its shares in Ahealth to Bidco in terms of the Offer. The Offer is subject to the suspensive conditions set out in 3.3 below. Upon the Scheme becoming operative, or alternatively Bidco acquiring all of the issued share capital of Ahealth pursuant to the alternative offer, an application will be made to the JSE to terminate the listing of the share capital of Ahealth from the JSE. 2. RATIONALE FOR THE OFFER Afrox and Ahealth issued a joint cautionary in July 2003 advising that Afrox was in the process of considering its strategic options with regard to its shareholding in Ahealth. This represented a unique opportunity for the BEE Consortium to acquire a business with a strong position in the private hospital and healthcare industry that would not have been possible to achieve through organic growth. Medi-Clinic and its holding company Remgro together with empowerment partners Brimstone and Mvelaphanda, seized this opportunity to introduce Black Economic Empowerment on a large scale to the private hospital and healthcare industry. Bidco will add significant value to Ahealth and its industry leading management team by constituting Ahealth as the first significant Black Economic Empowerment owned and controlled private hospital and healthcare group in South Africa. With the evolving South African national healthcare system, an empowered Ahealth will be ideally positioned for growth and profitability. The Offer significantly contributes to empowerment by increasing the spread of ownership of assets amongst historically disadvantaged persons. 3. TERMS OF THE OFFER The Offer consideration In terms of the Offer, Bidco will, subject to the fulfilment of the suspensive conditions detailed in paragraph 3.3, pay a cash consideration per share of R13.85. The cash consideration shall be escalated at an effective rate of 5.6% per annum from 1 October 2003, being the effective date, to the scheme operative date or the day on which the conditions of the alternative offer are fulfilled. For illustrative purposes, assuming the scheme operative date is 30 April 2004, the total consideration payable per Ahealth share is as follows: R Cash consideration 13.85 Escalation at an effective rate of 5.6% 0.45 per annum Offer consideration 14.30 Final dividend declared for the year 0.40 ended 30 September 2003* Composite amount 14.70 * Ahealth shareholders registered as such on 23 January 2004 will receive the final dividend of 40 cents per share declared by Ahealth on 29 October 2003 in respect of Ahealth"s financial year ended 30 September 2003. 3.2 Cash confirmation Rothschild has provided written confirmation to the satisfaction of the SRP that Bidco has sufficient resources to discharge its obligations in full in terms of the Offer. 3.3 Suspensive conditions The Offer is conditional upon the fulfilment of certain suspensive conditions including the following: 3.3.1 Afrox shareholders in general meeting approving the disposal by Afrox of its shareholding in Ahealth to Bidco; 3.3.2 the approval by the competition authorities in terms of Chapter III of the Competition Act, No. 89 of 1998, of the Offer; 3.3.3 the approval, to the extent necessary, of any regulatory authorities having jurisdiction over the Offer, including the SRP, the JSE and the Exchange Control Division of the South African Reserve Bank; 3.3.4 the High Court of South Africa granting an order convening a meeting (the "scheme meeting") of shareholders of Ahealth at which such shareholders ("scheme members") will consider and vote on the Scheme; 3.3.5 the Scheme being approved at the scheme meeting by a majority representing not less than three fourths (75%) of the votes exercisable by the scheme members present and voting whether in person or by proxy at the scheme meeting; and 3.3.6 the High Court sanctioning the Scheme. 3.4 Effective date The effective date, upon the conditions to the Offer being fulfilled, is 1 October 2003. 4. FINANCIAL EFFECTS The table below illustrates the financial effects of the Offer per Ahealth ordinary share based on various relevant market prices and the financial results of Ahealth for the year ended 30 September 2003. The unaudited pro forma financial effects have been prepared for illustrative purposes only to provide information on how the Scheme would have impacted an Ahealth shareholder. Due to the nature of the unaudited pro forma financial effects, it may not give a fair reflection of an Ahealth shareholder"s financial position after the completion of the Scheme, nor the effect on their future earnings. Before Offer Change Composite Change the Offer consideration (%) amount (%) (cents) (cents) (cents)
Market prices: Monday, 14 July 1155 (5) 1385 (1) 19.9 1425 (2) 23.4 2003 30 day weighted 1003 (6) 1385 (1) 38.1 1425 (2) 42.1 average Thursday, 13 1400 (7) 1394 (3) (0.4) 1434 (4) 2.4 November 2003 Net asset value 596 (8) 1385 (9) 132.4 1425 (9) 139.1 per share: Net tangible asset 541 (8) 1385 (9) 156.0 1425 (9) 163.4 value per share: Earnings per share: Attributable 136 (8) 87 (10) (36.0) 127 (10) (6.6) earnings Headline earnings 138 (8) 87 (10) (37.0) 127 (10) (8.0) Number of shares 224,117 224,117 224,117 in issue (`000) Weighted average 223,448 223,448 223,448 number of shares (`000) Notes: 1. The "Offer consideration" calculations have been determined based on a cash consideration of R13.85 at 1 October 2003 2. The "Composite amount" comprises the Offer consideration plus the final dividend of 40 cents per share declared by Ahealth on 29 October 2003 in respect of Ahealth"s financial year ended 30 September 2003 3. The "Offer consideration" as at Thursday, 13 November 2004, being the last practicable date prior the finalisation of this announcement, is escalated from 1 October 2003 to 13 November 2003 by the effective rate of 5.6% per annum 4. The "Composite amount" as at Thursday, 13 November 2004 is the "Offer consideration" as at Thursday, 13 November 2004 plus the final dividend of 40 cents per share declared by Ahealth on 29 October 2003 in respect of Ahealth"s financial year ended 30 September 2003 5. The closing market price per Ahealth ordinary share on the last trading date prior to the publication of the first cautionary announcement on Monday, 14 July 2003. 6. The volume weighted average of the closing price published per Ahealth ordinary share over the 30 trading days up to the publication of the first cautionary announcement published on Monday, 14 July 2003. 7. The closing market price per Ahealth ordinary share on Thursday, 13 November 2003, being the last practicable date prior the finalisation of this announcement. 8. Extracted from the Ahealth published audited results for the year ended 30 September 2003. 9. Assuming the Scheme became operative on 30 September 2003, the net asset value of the "Offer consideration" and "Composite amount" is the cash consideration of R13.85. 10. Assuming the Scheme became operative on 1 October 2002, the earnings per share in the "Offer consideration" assumes that the cash consideration of R13.85 is invested at 9% net of tax of 30%, being an after tax rate of 6.3%, per annum for the year ended 30 September 2003. The earnings per share in the "Composite amount" assumes that the cash consideration of R13.85 is invested at 9% net of tax of 30%, being an after tax rate of 6.3%, per annum for the year ended 30 September 2003 plus the final dividend of 40 cents per share declared by Ahealth on 29 October 2003 in respect of Ahealth"s financial year ended 30 September 2003. 11. Capital Gains Tax has not been taken into consideration in computing the pro-forma financial effects set out above. 5. UNDERTAKINGS, RECOMMENDATION AND OPINIONS Ahealth has appointed Deutsche Securities SA (Pty) Limited ("Deutsche") as independent adviser to advise the Board of Directors of Ahealth on the terms of the Offer. Deutsche has advised the Board of Directors of Ahealth that it has considered the terms and conditions of the Offer and is of the opinion that the terms and conditions are fair and reasonable to the Ahealth shareholders other than Afrox. The Board of Directors of Ahealth has considered the advice provided by Deutsche and the terms and conditions of the Offer and is of the opinion that the terms and conditions are fair and reasonable to the shareholders of Ahealth. Accordingly, the Board of Directors of Ahealth recommends that the Ahealth shareholders vote in favour of the Scheme, and will be voting their own shares in favour of the Scheme at the scheme meeting. Afrox has undertaken to Bidco that it will not dispose of, encumber, or grant any right over any of the Ahealth shares it owns other than pursuant to the Offer. 6. DOCUMENTATION AND ANNOUNCEMENTS The offer document will be posted to all Ahealth shareholders once the necessary approvals and consents have been obtained from, inter alia, the SRP and the JSE, and after Ahealth has received the necessary leave to convene the scheme meeting from the High Court. A further announcement containing full details of the relevant dates and times pertaining to the Offer will be published on SENS in due course. 7. WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT The further joint cautionary announcement dated 6 October 2003 regarding the strategic options of the relationship between Afrox and Ahealth is hereby withdrawn. Johannesburg 17 November 2003 Financial adviser to Bidco Independent adviser and transaction Rothschild sponsor to Ahealth Deutsche Securities Legal adviser to Bidco Sponsor to Ahealth Hofmeyr Herbstein & Gihwala Inc Nedbank Corporate Financiers Competition law advisers to Ahealth ABSA Corporate and Merchant Bank Edward Nathan & Friedland Investor relations to Bidco College Hill Reporting accountants PriceWaterhouseCoopers Date: 17/11/2003 09:00:10 AM Supplied by www.sharenet.co.za Produced by the JSE SENS Department